{
    "ticker": "KLDO",
    "name": "Kaleido Biosciences, Inc.",
    "description": "Kaleido Biosciences, Inc. is a biotechnology company focused on transforming human health through the modulation of the microbiome. Founded in 2015 and headquartered in Lexington, Massachusetts, Kaleido is dedicated to developing innovative therapies that harness the power of the microbiome to improve health outcomes. The company utilizes its proprietary Microbiome Metabolic Therapeutics platform to create a pipeline of products designed to treat a variety of diseases, including metabolic disorders, gastrointestinal diseases, and immune system conditions. Kaleido's approach is based on a deep understanding of the interactions between gut microbiota and human physiology, allowing it to develop targeted treatments that address the root causes of diseases rather than just symptoms. The company's lead product candidate, KB109, is designed to target metabolic disorders by rebalancing the gut microbiome. With a strong commitment to scientific innovation and patient-centric solutions, Kaleido is positioned at the forefront of the microbiome therapeutics field, aiming to bring transformative therapies to market that can significantly improve the quality of life for patients.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Lexington, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.kaleido.com",
    "ceo": "Dan Manos",
    "social_media": {
        "twitter": "https://twitter.com/KaleidoBio",
        "linkedin": "https://www.linkedin.com/company/kaleido-biosciences/"
    },
    "investor_relations": "https://investors.kaleido.com",
    "key_executives": [
        {
            "name": "Dan Manos",
            "position": "CEO"
        },
        {
            "name": "David D. Stein",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "KB109"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kaleido Biosciences, Inc. | Innovating Microbiome Therapeutics",
        "meta_description": "Kaleido Biosciences, Inc. is pioneering microbiome-based therapies to transform human health. Learn about our innovative approach and pipeline.",
        "keywords": [
            "Kaleido",
            "Microbiome",
            "Biotechnology",
            "Therapeutics",
            "Health Innovation"
        ]
    },
    "faq": [
        {
            "question": "What is Kaleido Biosciences known for?",
            "answer": "Kaleido Biosciences is known for its focus on microbiome-based therapies to improve human health."
        },
        {
            "question": "Who is the CEO of Kaleido Biosciences?",
            "answer": "Dan Manos is the CEO of Kaleido Biosciences, Inc."
        },
        {
            "question": "Where is Kaleido headquartered?",
            "answer": "Kaleido is headquartered in Lexington, Massachusetts, USA."
        },
        {
            "question": "What is Kaleido's lead product candidate?",
            "answer": "Kaleido's lead product candidate is KB109, designed to target metabolic disorders."
        },
        {
            "question": "When was Kaleido founded?",
            "answer": "Kaleido was founded in 2015."
        }
    ],
    "competitors": [
        "NVTA",
        "CRSP",
        "SGMO",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "BMY"
    ]
}